Full Press Release Details
Extraordinary General Meeting Results
accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 Immuron Limited (ASX: IMC; NASDAQ: IMRN or the
Company) advises that the shareholders of the Company passed all resolutions in the Notice of Meeting at the 2026 Extraordinary General
Meeting held earlier today.
resolutions put to the meeting were carried by way of a poll. All resolutions were carried. Details of the resolutions and the proxies
received in respect of each resolution are set out in the attached proxy summary.
release has been authorised by the Directors of Immuron Limited.
Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of infectious diseases.
proprietary technology is based on polyclonal immunoglobulins (IgG) derived from engineered hyper- immune bovine
colostrum. Immuron has the capability of producing highly specific immunoglobulins to any enteric pathogen and our products are orally
active. Bovine IgG can withstand the acidic environment of the stomach and is resistant to proteolysis by the digestive enzymes found
in the Gastrointestinal (GI) tract. Bovine IgG also possesses this unique ability to remain active in the human GI tract delivering its
full benefits directly to the bacteria found there. The underlying nature of Immuron's platform technology enables the development
of medicines across a large range of infectious diseases. The platform can be used to block viruses or bacteria at mucosal surfaces such
as the Gastrointestinal tract and neutralize the toxins they produce.
more information visit: https://www.immuron.com.au/ and https://www.travelan.com
Sign up to Immuron's Investor Hub: Here
press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements
relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking
statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing
and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the
timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our
SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our expectations or any changes in events, conditions, or circumstances on which
any such statement is based, except as required by law.
following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.
| Resolution details | Instructions given to validly appointed proxies (as at proxy close) | Number of votes cast on the poll (where applicable) | Resolution Result | If s250U | ||||||
| applies | ||||||||||
| Resolution | Resolution Type | For | Against | Proxy's Discretion | Abstain | For | Against | Abstain* | Carried / Not Carried | |
| 1. Ratification of prior issue of shares - Listing Rule 7.1 | Ordinary | 12,210,847 57.11% | 7,942,172 37.15% | 1,226,929 5.74% | 53,800 | 14,090,685 63.95% | 7,942,172 36.05% | 53,800 | Carried | NA |
| 2. Ratification of prior issue of shares - Listing Rule 7.1A | Ordinary | 12,210,847 57.11% | 7,942,172 37.15% | 1,226,929 5.74% | 53,800 | 14,090,685 63.95% | 7,942,172 36.05% | 53,800 | Carried | NA |